These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 31298375)

  • 1. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1.
    Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19.
    Wang Y; Lian YM; Ge CY
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5831-5839. PubMed ID: 31298334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
    Yu G; Zhong N; Chen G; Huang B; Wu S
    Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-125b-5p upregulation by TRIM28 induces cisplatin resistance in non-small cell lung cancer through CREB1 inhibition.
    Tan Q; Ma J; Zhang H; Wu X; Li Q; Zuo X; Jiang Y; Liu H; Yan L
    BMC Pulm Med; 2022 Dec; 22(1):469. PubMed ID: 36476351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
    Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
    BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
    Sui C; Meng F; Li Y; Jiang Y
    J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
    BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
    Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
    Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
    Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
    Chu D; Li P; Li Y; Shi J; Huang S; Jiao P
    Thorac Cancer; 2021 Nov; 12(21):2894-2906. PubMed ID: 34523261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
    Cheng R; Lu C; Zhang G; Zhang G; Zhao G
    Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.